Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
@article{Gershkovich2009PharmacokineticsAB, title={Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.}, author={P. Gershkovich and E. Wasan and Molly Lin and O. Sivak and C. Leon and J. G. Clement and K. Wasan}, journal={The Journal of antimicrobial chemotherapy}, year={2009}, volume={64 1}, pages={ 101-8 } }
OBJECTIVES
To assess the pharmacokinetics and biodistribution of amphotericin B (AmB) following oral administration in a novel mono/diglyceride-phospholipid formulation and to compare with intravenous (iv) administrations using commercial formulations.
METHODS
Rats were allocated into the following treatment groups: oral gavage of AmB dispersed in mono/diglyceride-phospholipid formulation at doses of 4.5 and 10 mg/kg; iv bolus administration of 0.8 mg/kg Fungizone; iv bolus of 5 mg/kg Abelcet… Expand
69 Citations
Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats
- Medicine
- Drug development and industrial pharmacy
- 2013
- 13
Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
- Biology, Medicine
- The Journal of antimicrobial chemotherapy
- 2010
- 22
- PDF
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
- Biology, Medicine
- Lipids in Health and Disease
- 2011
- 25
Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data
- Medicine
- The AAPS Journal
- 2011
- 19
Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition
- Chemistry, Medicine
- Pharmaceutical Research
- 2013
- 25
Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2020
Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection
- Medicine
- International journal of nanomedicine
- 2014
- 45
- PDF
Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
- Medicine
- Drugs
- 2016
- 120
- PDF
Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
- Medicine, Biology
- The Journal of antimicrobial chemotherapy
- 2010
- 17
- PDF
References
SHOWING 1-10 OF 48 REFERENCES
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.
- Chemistry, Medicine
- Antimicrobial Agents and Chemotherapy
- 1992
- 93
- Highly Influential
- PDF
Comparative Pharmacokinetics, Tissue Distributions, and Effects on Renal Function of Novel Polymeric Formulations of Amphotericin B and Amphotericin B-Deoxycholate in Rats
- Chemistry, Medicine
- Antimicrobial Agents and Chemotherapy
- 2000
- 28
- PDF
Effects of Lipid-Based Oral Formulations on Plasma and Tissue Amphotericin B Concentrations and Renal Toxicity in Male Rats
- Medicine
- Antimicrobial Agents and Chemotherapy
- 2003
- 44
- PDF
Toxicological Profile and Pharmacokinetics of a Unilamellar Liposomal Vesicle Formulation of Amphotericin B in Rats
- Medicine
- Antimicrobial Agents and Chemotherapy
- 1998
- 66
- Highly Influential
- PDF
Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
- Biology, Medicine
- The Journal of antimicrobial chemotherapy
- 2007
- 47
- PDF
Disposition kinetics of amphotericin B in rats. The influence of dose.
- Medicine
- Drug metabolism and disposition: the biological fate of chemicals
- 1992
- 7
Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients
- Medicine
- Antimicrobial Agents and Chemotherapy
- 1998
- 156
- PDF
Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats
- Medicine
- Pharmaceutical Research
- 2004
- 60
New dosing strategies for liposomal amphotericin B in high-risk patients.
- Medicine
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
- 2008
- 19
Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases
- Chemistry, Medicine
- European Journal of Clinical Pharmacology
- 2006
- 16